FLEMINGTON, N.J., July 18, 2014 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today...
FLEMINGTON, N.J., May 29, 2014 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today...
FLEMINGTON, N.J., May 15, 2014 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today...
Studies to determine recommended Phase II dose and safety profile of lead compound Will analyze relationship of biomarker to any anti-tumor activity observed FLEMINGTON, N.J., May 14, 2014...
FLEMINGTON, N.J., May 5, 2014 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today...
FLEMINGTON, N.J., April 7, 2014 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today...
FLEMINGTON, N.J., April 1, 2014 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today...
FLEMINGTON, N.J., March 26, 2014 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today...
FLEMINGTON, N.J., March 24, 2014 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today...
FLEMINGTON, N.J., March 5, 2014 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today...
기간 | 변동 | 변동 % | 시가 | 고가 | 저가 | 평균 일일 거래량 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0.0001 | 0.0001 | 0.0001 | 14983 | 0.0001 | CS |
12 | -0.0002 | -66.6666666667 | 0.0003 | 0.0003 | 0.0001 | 9989 | 0.0001 | CS |
26 | -0.0002 | -66.6666666667 | 0.0003 | 0.0003 | 0.0001 | 4994 | 0.0001 | CS |
52 | 4.2E-5 | 72.4137931034 | 5.8E-5 | 0.0003 | 5.8E-5 | 3757 | 0.00012027 | CS |
156 | -0.002 | -95.2380952381 | 0.0021 | 0.0021 | 1.0E-6 | 6366 | 7.33E-5 | CS |
260 | -0.0017 | -94.4444444444 | 0.0018 | 0.042 | 1.0E-6 | 63366 | 0.00487412 | CS |
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관